CTOs on the Move

Casma Therapeutics

www.casmatx.com

 
New discoveries are revealing the fundamental role of autophagy and lysosomal flux in maintaining cellular health. Furthermore, it is now appreciated that inadequate or aberrant autophagy contributes to a wide range of diseases. We are focused on boosting autophagy – pioneering novel therapeutic strategies to address unmet medical needs. We are creating a new target set for drug discovery and development, and advancing innovative paradigms to treat a broad set of illnesses that are either neglected or inadequately addressed today. Our growing team is driven to transform fundamental discoveries on autophagy into promising therapeutic medicines.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Casma Therapeutics raised $58.5M on 05/03/2018
Casma Therapeutics raised $50M on 09/10/2020

Similar Companies

BTI Products

BTI Products is a Bayfield, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mindstrong Health

Mindstrong was founded by some of the world`s leading authorities in neuroscience, oncology, and technology. It is based on their shared vision to redefine neuropsychiatric healthcare, transforming diagnosis and delivering precision therapy. Mindstrong builds on one of the founder`s patented biomarker platform developed over years of extensive clinical R&D.

Micell Technologies

Micell Technologies Inc is a Raleigh, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inflammatix

Inflammatix, Inc. is a venture-backed startup located in the San Francisco Bay Area that is building novel diagnostics for acute infections and sepsis based on our unique immune biomarkers. Approximately $10 billion / year is spent trying to diagnose acute infections, but current technologies that focus on `finding the bug` are (1) slow and (2) effective in fewer than 30% of cases. Inflammatix has developed a statistically rigorous, extensively validated diagnostic method that `reads` the immune system. Our HostDx™ tests report clinically actionable information on the presence, type (bacterial or viral), and severity of infection in all patients. They have been extensively validated and published in top-tier medical journals. After this initial product, Inflammatix plans to develop and commercialize additional novel diagnostic tests to address significant unmet clinical needs.

DiCE Molecules

At DiCE Molecules, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms.